Proteomics International Laboratories (ASX:PIQ) said the US Centers for Medicare & Medicaid Services set a reimbursement price of $390.75 for Promarker D, the company's predictive test for diabetic kidney disease, effective Jan.1, 2026, according to a Wednesday filing with the Australian bourse.
The company will now seek to obtain private health insurer coverage, the filing said.
Shares of the company rose 16% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.